Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27862796 | 0.91 | MDM2 (0.46) | MDM2GABRA2GABRB2ACP1 | |
| SCHEMBL1437051 | 0.90 | MDM2 (0.56) | MDM2GABRA2GABRB2TRPM8FAAH | |
| SCHEMBL9894039 | 0.89 | MDM2 (0.62) | MDM2 | |
| SCHEMBL1437712 | 0.85 | MDM2 (0.51) | MDM2GABRA2GABRB2TRPM8 | |
| SCHEMBL1443243 | 0.81 | MDM2 (0.49) | MDM2GABRA2GABRB2JAK2JAK3 | |
| SCHEMBL9893892 | 0.80 | MDM2 (0.78) | MDM2GABRA2GABRB2TRPM8 | |
| SCHEMBL1437160 | 0.79 | MDM2 (0.59) | MDM2GABRA2GABRB2 | |
| SCHEMBL9893837 | 0.78 | MDM2 (0.77) | MDM2GABRA2GABRB2TRPM8JAK2 | |
| SCHEMBL9893673 | 0.78 | MDM2 (0.69) | MDM2GABRA2GABRB2TRPM8 | |
| Lithium SCHEMBL9893840 | 0.78 | MDM2 (0.68) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885GABRA2 4293/4885GABRB2 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.